Table 1.
Demographics and clinical characteristics for patients with kidney failure secondary to IgAN
| Total (n = 282) | Recurrent IgAN (n = 80) | Nonrecurring IgAN (n = 202) | p values (recurrent vs. not) | |
|---|---|---|---|---|
| Age at transplant | 42 (33, 50) | 36 (28, 43) | 45 (36, 54) | <0.001 |
| <35 yr, n / N (%) | 82/282 (29) | 36/80 (45) | 46/202 (23) | <0.001 |
| 35–45 yr, n / N (%) | 87/282 (31) | 27/80 (34) | 60/202 (30) | 0.57 |
| >45 yr, n / N (%) | 113/282 (40) | 17/80 (21) | 96/202 (47) | <0.001 |
| Female sex, n / N (%) | 87/282 (31) | 28/80 (35) | 59/202 (29) | 0.39 |
| Recipient ancestry,1 n / N (%) | ||||
| European | 169/279 (61) | 54/79 (68) | 115/200 (58) | 0.10 |
| Hispanic/Latinx | 43/279 (15) | 10/79 (13) | 33/200 (16) | 0.85 |
| East Asian | 38/279 (14) | 7/79 (9) | 31/200 (15) | 0.18 |
| Black | 14/279 (5) | 4/79 (5) | 10/200 (5) | 1.0 |
| Other | 15/279 (5) | 4/79 (5) | 11/200 (6) | 1.0 |
| Allograft source, n / N (%) | ||||
| Living-related | 97/282 (34) | 34/80 (43) | 63/202 (31) | 0.10 |
| Living-unrelated | 54/282 (19) | 14/80 (17) | 40/202 (20) | 0.74 |
| Deceased donor | 131/282 (47) | 32/80 (40) | 99/202 (49) | 0.19 |
| Year of transplantation | 2011 (2006, 2015) | 2008 (2003, 2011) | 2012 (2008, 2015) | <0.001 |
| Donor ancestry,2 n / N (%) | ||||
| European | 172/237 (73) | 45/62 (73) | 127/175 (73) | 1.0 |
| Hispanic/Latinx | 32/237 (13) | 8/62 (13) | 24/175 (14) | 1.0 |
| East Asian | 7/237 (3) | 3/62 (5) | 4/175 (2) | 0.38 |
| Black | 17/237 (7) | 4/62 (6) | 13/175 (7) | 1.0 |
| Other | 9/237 (4) | 2/62 (3) | 7/175 (4) | 1.0 |
| Induction therapy,3 n / N (%) | ||||
| Thymoglobulin | 135/267 (50) | 27/69 (39) | 108/198 (55) | 0.04 |
| IL2R inhibitors | 76/267 (29) | 25/69 (36) | 51/198 (26) | 0.12 |
| Alemtuzumab | 37/267 (14) | 9/69 (13) | 28/198 (14) | 1.0 |
| No induction, n / N (%) | 14/267 (5) | 5/69 (7) | 9/198 (4) | 0.36 |
| Other induction, n / N (%) | 5/267 (2) | 3/69 (5) | 2/198 (1) | 0.11 |
| Steroid-free regimen, n / N (%) | 116/282 (41) | 28/80 (35) | 88/202 (44) | 0.23 |
| # HLA matches (0–6) | 2 (1, 3) | 3 (1, 4) | 2 (1, 3) | <0.001 |
| Recipient HLAs,4 n / N (%) | ||||
| B35 | 72/282 (26) | 24/80 (30) | 47/202 (23) | 0.29 |
| DQ5 | 99/250 (40) | 26/71 (37) | 73/179 (41) | 0.57 |
| DR3 | 37/282 (13) | 12/80 (15) | 25/202 (12) | 0.56 |
| DR15 | 51/282 (18) | 14/80 (18) | 37/202 (18) | 1.00 |
| DQ6 | 76/250 (30) | 20/71 (28) | 56/179 (31) | 0.65 |
| DQ2 | 77/250 (31) | 23/71 (32) | 54/179 (30) | 0.76 |
| Donor HLAs,5 n / N (%) | ||||
| B35 | 59/282 (21) | 17/80 (21) | 42/202 (21) | 1.0 |
| DQ5 | 86/248 (35) | 25/66 (38) | 61/182 (34) | 0.55 |
| DR3 | 51/282 (18) | 16/80 (20) | 35/202 (17) | 0.61 |
| DR15 | 60/282 (21) | 15/80 (19) | 45/202 (22) | 0.63 |
| DQ6 | 96/248 (39) | 25/66 (38) | 71/182 (39) | 1.0 |
| DQ2 | 90/248 (36) | 20/66 (30) | 70/182 (38) | 0.30 |
| Pretransplant DSA, n / N (%) | 15/276 (5) | 4/76 (5) | 11/200 (5.5) | 0.9 |
HLA match is calculated based on A, B, and DR antigens.
DSA, donor-specific autoantibodies; IgAN, IgA nephropathy; HLA, human leukocyte antigen.
1
Information on recipient ancestry was not available for 3 patients (1 recurrent and 2 nonrecurring).
2
Information on donor ancestry was not available for 45 patients (18 recurrent and 27 nonrecurring).
3
Information on induction therapy was not available for 15 patients (11 recurrent and 4 nonrecurring).
4
Recipient HLA-DQ typing was not available for 32 patients (9 recurrent and 23 nonrecurring).
5
Donor HLA-DQ typing was not available for 34 patients (14 recurrent and 20 nonrecurring).